<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="90892">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02127853</url>
  </required_header>
  <id_info>
    <org_study_id>SerialCataractGaba</org_study_id>
    <nct_id>NCT02127853</nct_id>
  </id_info>
  <brief_title>Effect of Gabapentin on Pain of the Second Cataract Surgery</brief_title>
  <official_title>The Effect of Pretreated Gabapentin on Hyeralgesia Occurring in the Second Operation in Staged Bilateral Cataract Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <authority>Korea: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gabapentin pretreatment may reduce hyperalgesia occurring at the second surgery in serial,
      bilateral cataract surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hyperalgesia occurring at the second operation in bilateral eye surgery  is  well known, and
      mechanism of central sensitization might be involved. Gabapentin is known to lower the
      effect of central sensitization, and its effect on acute postoperative pain has been
      reported. Therefore, pretreatment of gabapentin after first operation may reduce the pain at
      second operation.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>proportion of subjects who answer that &quot;pain was greater&quot; in the second eye surgery</measure>
    <time_frame>Intra operative (pain while fluid injection to anterior chamber)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>perioperative pain</measure>
    <time_frame>end of surgery, post-op 1hr at PACU, at out-patient ward, post-op 1 day</time_frame>
    <safety_issue>No</safety_issue>
    <description>evaluation of overall perioperative pain</description>
  </secondary_outcome>
  <other_outcome>
    <measure>satisfaction</measure>
    <time_frame>intra operative</time_frame>
    <safety_issue>No</safety_issue>
    <description>evaluation of satisfaction of both operator and patient</description>
  </other_outcome>
  <other_outcome>
    <measure>anxiety</measure>
    <time_frame>baseline (at OR room arrival, just before sterile draping)</time_frame>
    <safety_issue>No</safety_issue>
    <description>evaluation of patient's anxiety</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Hyperalgesia</condition>
  <arm_group>
    <arm_group_label>Gabapentin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>gabapentin pretreatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo drug pretreatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gabapentin</intervention_name>
    <description>100 mg tid of gabapentin is prescribed to the patient for 1 week after the first eye surgery</description>
    <arm_group_label>Gabapentin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>the same regimen of placebo drug is prescribed to the patient for 1 week after the first eye surgery</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient of ASA(American Cociety of Anesthesiology) class I, II, III between age 20 to
             80, scheduled for serial bilateral cataract surgery(1 weel interval)

        Exclusion Criteria:

          -  refuse to participate

          -  BMI&lt;16 or BMI &gt;30

          -  severe cardiovascular, pulmonary, renal disease

          -  alcohol or drug abuse

          -  currently taking CNS(central nervous system) inhibitory drugs

          -  taking antiacids

          -  depressive disorder pregnancy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 30, 2014</lastchanged_date>
  <firstreceived_date>April 29, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Hee-Pyoung Park</investigator_full_name>
    <investigator_title>associate professor</investigator_title>
  </responsible_party>
  <keyword>serial cataract surgery</keyword>
  <keyword>hyperalgesia</keyword>
  <keyword>gabapentin</keyword>
  <keyword>central sensitization</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hyperalgesia</mesh_term>
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gabapentin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
